Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently

Chen, Zhaoqi; Liu, Yan; Chen, Nianci; Xing, Haiyan; Tian, Zheng; Tang, Kejing; Rao, Qing; Xu, Yingxi; Wang, Ying; Wang, Min; Wang, Jianxiang

doi:10.1007/s11427-022-2173-9

Cited by 7 publications

(6 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After that, castor oil (CO, 4.7 g, 1 eqv) was added and stirred at 70°C for another 3 h. Finally, –NCO peak was fully disappeared at 2270 cm −1 (Figure 2a (black line)). The –NH stretching vibrations of the urethane group ranges from 3230 to 3380 cm −1 indicates the polyurethane (Figure 2a (black line)) 19 . However, –C=O stretching vibrations 1670–1750 cm −1 was overlapped between urethane (–OC(=O)–NH–) and ester (–C(=O)–O–) functionalities.…”

Section: Resultsmentioning

confidence: 98%

“…A mixture of PCL‐diol (10.1 g, 1 eqv), TDI (1.45 mL, 2 eqv), and DBTDL (1 mol%) were heated at 70°C for 1 h (Table 1, entry 1 (first step)). The decrement of the –NCO peak at 2270 cm −1 and –OH peak at 3596 cm −1 (Figure 2a (green line)) indicates the condensation of –OH and –NCO functionality and the generation of prepolymer 19 . After that, castor oil (CO, 4.7 g, 1 eqv) was added and stirred at 70°C for another 3 h. Finally, –NCO peak was fully disappeared at 2270 cm −1 (Figure 2a (black line)).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Harnessing leather waste in polymer matrix for sustainable smart shape‐stable phase change materials

Sarkar,

Samanta,

Chaudhuri

et al. 2024

J of Applied Polymer Sci

View full text Add to dashboard Cite

The utilization of leather waste (LW) in a polyurethane (PU) matrix makes a smart and novel shape stable phase change material (SSPCM). This is essential for sustainability as it reduces landfill waste after use. The PU is synthesized in bulk with a 90% yield, using biodegradable polycaprolactone diol and bio‐based polyol (castor oil), along with tolylene‐2,4‐diisocyanate. PL and PLG composites are prepared by blending of constituent components PU (P), LW (L), and poly(glycidyl methacrylate) (PGMA, G), as specified by their code names. Role of LW (hydrogen bonding and chemical crosslinking) and morphology are elucidated by FTIR and SEM, respectively. Self‐healing time (2 h), shape fixity ratios (Rf) (PL: 60–80% and PLG: 60–70%) and shape recovery ratios (Rr) (100% for both) are determined at 60°C. PLG displays faster shape recovery in water (<30 s) compared to air (>300 s). Shape stability and thermal properties of the SSPCM are examined using the temperature responsive leakage study, TGA, and DSC. This research introduces a new approach for using leather waste (LW) in SSPCM, with self‐healing and 100% Rr. This material may find application where SSPCM with high durability and flexibility is essential such as textile and footwear materials.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Harnessing leather waste in polymer matrix for sustainable smart shape‐stable phase change materials

Sarkar,

Samanta,

Chaudhuri

et al. 2024

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…We evaluated the effect of vIL7FL on DC populations in the tumor-bearing hemisphere. In the steady-state mouse brain, subcutaneous Flt3L delivery has been shown to increase antigenpresenting cDC populations (82). Additionally, these cDCs arose from the differentiation of pre-DC progenitors that had migrated into the brain.…”

Section: Discussionmentioning

confidence: 99%

“…Compared with traditional CAR-T cells, CAR-CAT cells had a lower oxidation state with less ROS accumulation in both basal and activated states, while maintained stronger anti-tumor activity even at high H 2 O 2 levels. These results showed that protecting CAR-T cells from exhaustion mediated by tumor-associated oxidative stress could significantly improve their efficacy (82). To date, ICB targeting PD-1 and programmed cell death ligand 1 (PD-L1) have achieved clinical success for solid tumors (83).…”

Section: Tme Leads To Premature Exhaustion Of Car-t Cellsmentioning

confidence: 99%

Emerging Learnings in Cell Therapy: Novel Binding Domains, Universal CAR-T Cells, and More

2024

Frontiers Research Topics

View full text Add to dashboard Cite

Frontiers is more than just an open access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers journal seriesThe Frontiers journal series is a multi-tier and interdisciplinary set of openaccess, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers journal series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to qualityEach Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public -and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics?Frontiers Research Topics are very popular trademarks of the Frontiers journals series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area.

show abstract

“…Our previous study demonstrated that scFv function can be influenced by the type of linker used and the order of the heavy and light chain, even with the same nucleotide sequences [ 31 ]. Therefore, several linkers and different arrangements of CD3VL/CD3VL/CD19VL/CD19VH were evaluated to optimize the functionality of the dual-antibody in this study, while we only present the structures in which DuAb and EDuAb exhibit the best capacity in eliminating tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy

Chen¹,

Liu²,

Peng³

et al. 2023

Exp Hematol Oncol

Self Cite

View full text Add to dashboard Cite

Background T cell-redirecting bispecific antibodies establish a connection between endogenous T cells and tumor cells, activating T cells function to eliminate tumor cells without ex vivo genetic alteration or manipulation. Here, we developed a novel dual-specific antibody (DuAb) and an enhanced DuAb (EDuAb) with different stimulation signal to activate T cells, and evaluated their impact on the treatment of acute lymphoblastic leukemia (ALL). Methods The expression plasmids of the DuAb and EDuAb containing CD80 molecule were constructed by cloning heavy chain and light chain variable fragments from anti-human CD19 (HI19a) and CD3 (HIT3a) monoclonal antibody hybridomas, respectively. The activation and the anti-tumor efficacy of human T cells mediated by DuAb and EDuAb were evaluated in vitro. B-cell ALL xenograft NSG mouse model was established to investigate the therapeutic effect in vivo. Results EDuAb promoted the optimal expansion of primary human T cells with low expression of inhibitory markers in vitro than DuAb did. Both DuAb and EDuAb showed a similar capability in inducing healthy donor T cells to specifically eliminate B-ALL cell lines and primary blasts from patients. The similar ability was also observed in the patient-derived T cells. In vivo study showed that both DuAb and EDuAb significantly alleviated tumor burden and extended survival of B-ALL xenograft NSG mice. The median survival of PBS, DuAb and EDuAb treatment groups were 27, 38 and 45 days, respectively. The phenotype of T cells and cytokine release in peripheral blood (PB) of B-ALL xenograft NSG mice on day 24 were analyzed as well. The results showed that the proportion of CD8+ T cells and cytokine levels, including IL-2, IFN-γ and TNF-α, were higher in the EDuAb group than that of DuAb. Moreover, both DuAb and EDuAb significantly decreased the residual leukemia cells in PB of B-ALL xenograft NSG mice. Conclusions Both DuAb and EDuAb showed great potential as novel treatments for B-ALL in clinical applications. However, compared to DuAb, EDuAb showed a significant advantage in promoting the proliferation and survival of T cells. Furthermore, EDuAb showed a better promising effect on eliminating tumor cells and extending survival in vivo, which provides new insights for the development of new multi-specific antibodies.

show abstract

Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently

Cited by 7 publications

References 51 publications

Harnessing leather waste in polymer matrix for sustainable smart shape‐stable phase change materials

Harnessing leather waste in polymer matrix for sustainable smart shape‐stable phase change materials

Emerging Learnings in Cell Therapy: Novel Binding Domains, Universal CAR-T Cells, and More

Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy

Contact Info

Product

Resources

About